Taketoshi Ogawa

The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al. · British Journal of Pharmacology · 2000 · 235 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara et al. · Journal of Thrombosis and Haemostasis · 2007 · 218 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type G_i‐linked P2T antagonist, CS‐747

Atsuhiro Sugidachi, Fumitoshi Asai, Kenji Yoneda et al. · British Journal of Pharmacology · 2001 · 110 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor

Michihiro Hasegawa, Atsuhiro Sugidachi, Taketoshi Ogawa et al. · Thrombosis and Haemostasis · 2005 · 63 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species

Y. Niitsu, Atsuhiro Sugidachi, Taketoshi Ogawa et al. · European Journal of Pharmacology · 2007 · 47 citations

Medicine, Pharmacokinetics, Pharmacology +15